How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS - Wikidata - wikimedia - TriplyDB

How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS

How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS

http://www.wikidata.org/entity/Q57711927

about

Proteomics and metabolomics in renal transplantation-quo vadis?Recent advances in mass spectrometry-based proteomics of gastric cancer Long term metabolic syndrome induced by a high fat high fructose diet leads to minimal renal injury in C57BL/6 mice Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.Current state of the art for enhancing urine biomarker discovery.Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications.Screening for obstructive sleep apnoea in obesity and diabetes--potential for future approaches.Review of the CE-MS platform as a powerful alternative to conventional couplings in bio-omics and target-based applications.CE-MS for metabolomics: developments and applications in the period 2012-2014.Advances in urinary proteome analysis and applications in systems biology.Mass spectrometry protein tests: ready for prime time (or not).The long path towards implementation of clinical proteomics: Exemplified based on CKD273.Continued growth in clinical proteomics.Urinary peptidomics in kidney disease and drug research.Rapid determination of globin chains in red blood cells by capillary electrophoresis using INSTCoated fused-silica capillary.

P2860

Q27024418-6C2706DE-867C-4D5B-BA0F-C30CB8B118A8 Q28075514-AC031F86-9C39-434B-9AD6-B01D4054A783 Q28534010-BFCC83EB-BD7D-41B8-92A0-AE5A80D17911 Q33985444-C948BE58-4A64-4C19-AA53-7CA1B855EE18 Q36032361-CB60C2AD-E313-412D-9029-20394099CE45 Q38091336-7F0C3E36-6161-4A7A-8717-486890B3D623 Q38099038-6BA66196-2BBD-4A92-B112-0E119C068C19 Q38184491-1FD44DE8-BE64-410F-A5FA-6CD36848F714 Q38257362-88E50863-3F34-45E7-AC8B-AB80E14B54E3 Q38269864-0CAFBFD0-D084-42EC-A865-6A1BA618C738 Q38799731-C79EEF79-F58A-4E43-88A9-BA4BC927ED72 Q39055330-668897DB-AE70-485F-A959-F03D954BAB7D Q44777292-81C423A9-95AE-400C-B9B5-BDC9CC82AAAD Q47781932-9F059EC1-54C2-49BA-9B82-FED73C11FB28 Q50475593-F1B75CE6-76A4-4701-8B09-2601B0AE3B7A

P2860

How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS

http://www.wikidata.org/entity/Q57711927

description

im September 2012 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2012

@uk

name

How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS

@en

How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS

@nl

type

label

How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS

@en

How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS

@nl

prefLabel

How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS

@en

How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS

@nl

P1433

Q57711927-3F70B6D1-FF41-4664-BE30-B3B2A30C5201

P1476

Q57711927-4A756CBE-587D-4807-B01D-905F1388A89C

P2860

Q57711927-06390655-75E1-4795-B25E-3AFC2AFD6F98

Q57711927-0B301BC6-236C-470C-952E-0125CA3CA075

Q57711927-0C7B1692-5865-418C-A876-EA54873BE8EF

Q57711927-144DBF19-1B9F-40F4-8DF8-4FA137EF958A

Q57711927-18B17E01-A28B-49F5-9FB6-BF734287E790

Q57711927-239EA5D1-1D77-496B-81CA-92F0F8DFBE53

Q57711927-2627DF24-6069-4585-AF84-791D3F9ACA3A

Q57711927-26A7E3C3-2A53-4720-ACAA-547CE3432844

Q57711927-297CC3AF-7D8B-45B7-B09A-B2ED367A0A09

Q57711927-2AAACDB7-BE95-43BF-A0BC-AEC880A809C8

P304

Q57711927-05CDA38A-7AA6-42F3-A97E-610BB6EB5409

P31

Q57711927-D7895FDB-1F87-49CF-BF3D-2D344C44C9E3

P356

Q57711927-CCA603D3-9D15-40D9-9C1C-0CB736EF9C13

P433

Q57711927-B4065D65-E343-40E1-9254-910E3A989949

P478

Q57711927-B1D587AE-0169-47BF-99FF-CDA3A92E77A2

P50

Q57711927-9BB4C7F3-ED49-42F0-B09E-C0832EB0B12D

P577

Q57711927-200000DA-E271-4889-B049-42AEDAB9D38E

P698

Q57711927-BBCC35B6-A978-4EF9-A871-9F17D9804CC1

P356

P1433

Proteomics - Clinical Applications

P1476

How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS

@en

P2860

Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology

A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy

Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease.

Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis

CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics.

Discovery and validation of urinary biomarkers for prostate cancer

Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments

Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis.

Non-invasive markers of ureteropelvic junction obstruction.

Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria

P304

437-442

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PRCA.201200027

http://www.w3.org/2001/XMLSchema#string

P433

9-10

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-09-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22821927

http://www.w3.org/2001/XMLSchema#string